A second media entity Street Register, which has 49 Twitter followers, also has positive newsy-looking posts on USRM. When I checked, the Oracle Dispatch has 42 Twitter followers. For instance, something called The Oracle Dispatch, has run quite a few stories on USRM. What exactly are the specific news/financial Internet outlets themselves that are running so many stories on USRM and in some cases other stem cell biotechs? They generally are not big, mainstream media kinds of sources. Does it all add up to a logical rationale for a big stock price jump? Or are media impacting investors? Both?Īs a side note, USRM announced with some fanfare its RMAT application to the FDA as mentioned in one of the pieces listed above in the Google results, but no decision has been announced. What’s its status? Could it have been rejected? More data requested? The turnaround time on the RMATs seems pretty fast generally. Could those be it?Īnother item mentioned “positive” financial results and there was some indication of new investments in the firm.
#Stem cell stock price trial#
Is there something not widely known that is exciting investors and prompting all these media items? The company also announced a deal to open stem cell clinics in the Middle East and the “reactivation status” of a trial by the FDA (not sure what that will mean practically speaking for the company). Kristin Comella, CSO of USRM, did publish a short paper prior to the beginning of the stock run up but it wasn’t a breakthrough pub in my opinion. What’s going on with USRM specifically? Is it just outperforming other stem cell biotechs in terms of legit PR and in other concrete ways?
The short answer is “who knows?”, but USRM and some other stem cell businesses in recent years have been the subjects of a large number of generally positive newsy items on the web. Since essentially all of these (and other similar ones over a longer period of time) apparently independent news-ish items on USRM were positive and not one mentioned the blinded patients, I wondered how independent the news/investing outlets involved really were. You can see a recent screenshot below of an example of a cluster of generally positive pieces on USRM earlier this month. Even so, USRM stock has gone on to spike up. Around this same period of time I noticed an unusually large number of items popping up about USRM in the Google News Feed for various searches. USRM, formerly known as Bioheart, made news late last year in a way one might think investors would worry about as it was linked to the blinding of three of its customers.
($USRM), a stem cell clinic business, have caught my eye this year. Upbeat pieces that are newsy in feel about one particular company, US Stem Cell, Inc.
#Stem cell stock price series#
Hyped press releases (PR) that might arguably be in part fake news are nothing new and there has always been stock pumping, but another more recent phenomenon consists of more extensive series of news-like pieces about publicly-traded companies from seemingly independent third parties, generally extremely positive in tone. One of my Top 20 Predictions for Stem Cells for 2017was that fake stem cell news would mushroom.Īre these fake news? Standard pumping? Is there a difference? Something else entirely? Let’s take a look at one case study. More broadly, the SEC is cracking downon the mess that is fake biotech news, but what about fake news on stem cell biotechs more specifically? Already in the past year I’ve seen examples of possible stem cell fake news.
Is there a proliferating stem cell fake news problem in the biotech world?
0 kommentar(er)
